Prosecution Insights
Prosecution Insights
10 pending office actions • 7 art units • 9 examiners • 0 of 10 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (30%) |
| Double-patenting + other | 4 (40%) |
| Multi-statute (no §101) | 3 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHO, DAVID H | 2 | 37.5% | +73.5% |
| BUTTICE, AUDREY L | 1 | 47.1% | +26.0% |
| HIBSHMAN, SARAH GRACE | 1 | 38.8% | +43.8% |
| SKOKO III, JOHN JOSEPH | 1 | 53.2% | +57.5% |
| PUTTLITZ, KARL J | 1 | 69.1% | +18.5% |
| LEE, HOI YAN NMN | 1 | 41.0% | +79.2% |
| ZARA, JANE J | 1 | 70.9% | +16.1% |
| GIBBS, TERRA C | 1 | 63.9% | +10.4% |
| BAKSHI, PANCHAM | 1 | 77.0% | +30.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17415759 | DRUG CONJUGATE | ZARA, JANE J | 30d overdue |
| 18012715 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | BUTTICE, AUDREY L | 15d |
| 17312104 | Saponin Conjugates | BAKSHI, PANCHAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17415759 | DRUG CONJUGATE | ZARA, JANE J | 30d overdue |
| 18012710 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | PUTTLITZ, KARL J | 14d |
| 18012715 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | BUTTICE, AUDREY L | 15d |
| 18012741 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | SKOKO III, JOHN JOSEPH | 26d |
| 17629598 | BIOACTIVE SAPONIN LINKED TO A FUNCTIONAL MOIETY | LEE, HOI YAN NMN | 34d |
| 18012791 | HYDRAZONE-BASED SAPONIN DERIVATIVES | HIBSHMAN, SARAH GRACE | — |
| 18012729 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CHO, DAVID H | — |
| 18012778 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | CHO, DAVID H | — |
| Art Unit | Apps |
|---|---|
| 1693 | 4 |
| 1647 | 1 |
| 1643 | 1 |
| 1646 | 1 |
| 1637 | 1 |
| 1635 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18012715 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | BUTTICE, AUDREY L | 1647 | §103§112Other | Final Rejection | 15d | Pending | Dec 23, 2022 |
| 18012791 | HYDRAZONE-BASED SAPONIN DERIVATIVES | HIBSHMAN, SARAH GRACE | 1693 | §103§112DP | Final Rejection | — | Pending | Dec 23, 2022 |
| 18012729 | CONJUGATE OF A SINGLE DOMAIN ANTIBODY, A SAPONIN AND AN EFFECTOR MOLECULE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, THERAPEUTIC USE OF SAID PHARMACEUTICAL COMPOSITION | CHO, DAVID H | 1693 | §103DP | Final Rejection | — | Pending | Dec 23, 2022 |
| 18012741 | COMBINATION COMPRISING AN ADC OR AN AOC COMPRISING A VHH, AND A SAPONIN OR A LIGAND-SAPONIN CONJUGATE | SKOKO III, JOHN JOSEPH | 1643 | §103Other | Final Rejection | 26d | Pending | Dec 23, 2022 |
| 18012778 | THERAPEUTIC COMBINATION OF GALNAC-OLIGONUCLEOTIDE CONJUGATE AND SAPONIN, AND USES THEREOF | CHO, DAVID H | 1693 | §103§112DP | Final Rejection | — | Pending | Dec 23, 2022 |
| 18012710 | CONJUGATE OF SAPONIN AND SINGLE-DOMAIN ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING SAID CONJUGATE, THERAPEUTIC USE THEREOF | PUTTLITZ, KARL J | 1646 | §103Other | Final Rejection | 14d | Pending | Dec 23, 2022 |
| 17629598 | BIOACTIVE SAPONIN LINKED TO A FUNCTIONAL MOIETY | LEE, HOI YAN NMN | 1693 | §103Other | Final Rejection | 34d | Pending | Jan 24, 2022 |
| 17415759 | DRUG CONJUGATE | ZARA, JANE J | 1637 | §103§112Other | Final Rejection | 30d overdue | Pending | Jun 18, 2021 |
| 17312476 | BIOLOGICALLY ACTIVE CLUSTER OF MOLECULES | GIBBS, TERRA C | 1635 | §112DP | Final Rejection | — | Pending | Jun 10, 2021 |
| 17312104 | Saponin Conjugates | BAKSHI, PANCHAM | 1623 | §102§112 | Non-Final OA | — | Pending | Jun 09, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial